buyout – Health

Years after Cubist buyout, Merck scores a new Zerbaxa indication. Can it jump-start sales?

Merck hasn’t exactly made a fortune on its $ 9.5 billion Cubist Pharmaceuticals buyout, but now, a next-gen antibiotic it acquired in that deal has a brand-new indication that could help jump-start sales. On Monday, the FDA approved that drug, Zerbaxa, to treat adults with hospital-acquired and ventilator-associated pneumonia. It’s an add-on to Zerbaxa’s original approvals—to treat complicated… Read More »

Does Bristol-Myers Squibb’s new activist investor want to stall its Celgene buyout?

Analysts and investors have both expressed concerns over Bristol-Myers Squibb’s $ 74 billion Celgene deal agreement. And an activist may be joining that list. Known agitator Starboard Value has taken a stake in the New Jersey drugmaker, Bloomberg’s sources say, though the size of that stake and the hedge fund’s plans are still unclear. A… Read More »